

# Vagus Nerve Stimulation Associated with Fewer Deaths in Hospitalized COVID-19 Patients

*Dr. Patrick Nemechek reports on a promising clinical trial in the Journal of Clinical and Experimental Immunology*

OVERLAND PARK, KANSAS, UNITED STATES, December 2, 2020

/EINPresswire.com/ -- [Nemechek](#)

[Technologies](#) is proud to announce publication of a peer-reviewed research article by its CEO, Patrick Nemechek D.O. Entitled, 'Transcutaneous Vagus Nerve Stimulation is Associated with Lower Mechanical Ventilation and Mortality in COVID-19 Patients: An interim Safety Analysis', the study reveals that transcutaneous vagus nerve stimulation (tVNS) is safe and potentially beneficial for hospitalized patients with COVID-19 pneumonia. Patients meeting clinical criteria received tVNS therapy for 5 minutes 2-4 times per day with the Nemechek Technologies Vitality Smartcable® neuromodulator.



Nemechek Technologies Vitality Smartcable Transcutaneous Vagus Nerve Stimulator is the first neuromodulator to run on your smartphone.

Patient outcomes included infrequent use of mechanical ventilation, and a high rate of survival. Interim analysis found the mortality rate and the frequency of mechanical ventilation to be less than almost all other large COVID-19 cohorts. The study, an ongoing single-arm, uncontrolled open-label, observational trial to assess (tVNS) in hospitalized SARS-CoV-2 infected subjects, is being conducted at Hospital Zonal Virgen Del Carmen in Zarate, Buenos Aires, Argentina.

[Read the Article](#)

“We are extremely encouraged by the reduced mortality in patients receiving tVNS therapy. The trial is moving forward to achieve its planned total enrollment, and we will publish further results once all 50 subjects have been treated.” – Patrick Nemechek D.O.

#### About Nemechek Technologies, LLC

Nemechek Technologies, LLC is a privately held manufacturer of bio-electronic medicine. Their first product, the Vitality Smartcable<sup>®</sup>, is the first tVNS neuromodulator that runs on a smartphone.

With 20 years' experience as an HIV physician and researcher, Dr. Nemechek was awarded U.S. Patent No. 10,335,396 for his method of lowering inflammation and reversing autonomic nervous system damage. The [Nemechek Protocol<sup>®</sup>](#), which focuses on reducing chronic inflammation, includes the use of transcutaneous vagus nerve stimulation. Dr. Nemechek has treated more than 1,000 patients with vagus nerve stimulation therapy over the past ten years at his clinic near Phoenix, Ariz.

Mike Nemechek  
Nemechek Technologies, LLC  
+1 913-219-1239

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/531807644>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire<sup>™</sup>, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.